Skip to main content Skip to search Skip to main navigation

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Key elements under discussion

The revision will be focused and limited in scope, addressing in particular:

  • Premises requirements
    Reassessment of the applicability of general GMP requirements to closed, pressurised gas manufacturing systems.
  • Technological developments
    Consideration of modern safety features such as gas-specific couplings, elimination of containers without residual pressure valves and adapted valve/residual gas checks to reduce contamination risks.
  • Cylinders with integrated pressure regulator flowmeters
    Clarification of inspection requirements before and after refilling and definition of control frequencies; inclusion of cryogenic containers.
  • Medicinal liquid oxygen supply to hospitals
    Strengthening and clarification of documentation and quality assurance requirements for the filling of the hospital’s tank evaporation units.
  • Batch certification (in addition to Annex 16)
    Assessment of potential specific provisions for medicinal gases, including QP availability and possible remote certification aspects.
  • Qualification of facilities and containers
    Clarification regarding qualification of production plants, mobile/stationary tanks and reusable containers.

Timeline

  • Public consultation until 11 April 2026
  • Draft guideline: November 2026
  • Finalisation: 2027


Quelle:

EMA: Concept paper on revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 6 Manufacture of Medicinal Gases

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next